Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during the period 1984-1997

Journal of Biological Regulators and Homeostatic Agents

Volumn 12, Issue SUPPL. 2, 1998, Pages 32-34

  Tambussi, G ^a   Boeri, E ^a   Carrera, P ^a   Gianotti, N ^a   Lazzarin, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Enotypic analysis; HIV 1 + na ve; Primary HIV infection; RTIs

Indexed keywords

NUCLEOSIDE ANALOG; ZIDOVUDINE;

ADULT; CONFERENCE PAPER; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; SEROCONVERSION; VIRUS GENE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031840488     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Havlir DV and Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124: 984-94.
2. Welles SL, Jackson JB, Yen-Lieberman B et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996; 174: 696-703.
3. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced HIV infection. J Infect Dis 1996; 174: 704-12.
4. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-1 infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-8.
5. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-31.
6. Phillips AN, Eron J, Bartlett J, et al. Corrispondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical diseases in infected individuals. AIDS 1997; 11: 169-70.
7. Gao WY, Agbaria R, Dricoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2', 3'-dideoxynucleoside analogs in resting and activated cells. J Biol Chem 1994; 269: 12633-8.
8. Gao WY, shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Biol Chem 1993; 91:2326-33.
9. Conlon CP, Klenerman P, Edwards A, et al. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994: 169; 411-5.
10. Quigg M, Rebus s, France AJ, et al. Mutation associated with zidovudine resistance in HIV-1 among recent seroconvertors. AIDS 1997; 11: 835-6.
11. Imrie A, Carr A, Duncombe C, et al. Prmary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. J Infect Dis 1996; 174: 195-8.
12. Boom R., Sol C. J. , Salimans M. M. et al. Rapid and simple method for purification of nucleic acids. J Clin Microb 1990; 28: 495-503.
13. Schnatz IRF, Larder B, Mellors JW. Mutations in retroviral genes associated with drug resistance. International Antiviral News, special issue, 1997.
14. Carpenter CJ, Fischl MA, Hammer SM, et al. JAMA 1997; 277: 1962-9